Fulgent Genetics EBITDA Margin 2015-2025 | FLGT
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Fulgent Genetics (FLGT) over the last 10 years. The current EBITDA margin for Fulgent Genetics as of March 31, 2025 is .
| Fulgent Genetics EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-03-31 | $0.29B | $-0.05B | -18.15% |
| 2024-12-31 | $0.28B | $-0.05B | -18.73% |
| 2024-09-30 | $0.28B | $-0.07B | -24.46% |
| 2024-06-30 | $0.29B | $-0.05B | -17.53% |
| 2024-03-31 | $0.29B | $-0.05B | -17.71% |
| 2023-12-31 | $0.29B | $-0.05B | -18.28% |
| 2023-09-30 | $0.29B | $-0.05B | -18.47% |
| 2023-06-30 | $0.31B | $-0.05B | -15.26% |
| 2023-03-31 | $0.37B | $-0.01B | -3.01% |
| 2022-12-31 | $0.62B | $0.22B | 34.89% |
| 2022-09-30 | $0.80B | $0.40B | 49.56% |
| 2022-06-30 | $0.93B | $0.55B | 59.68% |
| 2022-03-31 | $0.95B | $0.63B | 66.35% |
| 2021-12-31 | $0.99B | $0.69B | 69.89% |
| 2021-09-30 | $1.04B | $0.77B | 73.94% |
| 2021-06-30 | $0.91B | $0.67B | 73.08% |
| 2021-03-31 | $0.77B | $0.57B | 73.09% |
| 2020-12-31 | $0.42B | $0.29B | 69.67% |
| 2020-09-30 | $0.14B | $0.07B | 48.89% |
| 2020-06-30 | $0.04B | $0.00B | 9.30% |
| 2020-03-31 | $0.03B | $0.00B | 5.88% |
| 2019-12-31 | $0.03B | $0.00B | 6.45% |
| 2019-09-30 | $0.03B | $0.00B | 6.90% |
| 2019-06-30 | $0.03B | 0 | 0.00% |
| 2019-03-31 | $0.02B | $0.00B | -4.55% |
| 2018-12-31 | $0.02B | $0.00B | -9.09% |
| 2018-09-30 | $0.02B | $0.00B | -20.00% |
| 2018-06-30 | $0.02B | $-0.01B | -26.32% |
| 2018-03-31 | $0.02B | $-0.01B | -26.32% |
| 2017-12-31 | $0.02B | $0.00B | -10.53% |
| 2017-09-30 | $0.02B | $0.00B | 9.52% |
| 2017-06-30 | $0.02B | $0.00B | 14.29% |
| 2017-03-31 | $0.02B | $0.00B | 20.00% |
| 2016-12-31 | $0.02B | $0.00B | 16.67% |
| 2016-06-30 | $0.01B | $0.00B | 20.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.560B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.594B | 60.55 |
| Hims & Hers Health (HIMS) | United States | $12.830B | 133.30 |
| Doximity (DOCS) | United States | $11.392B | 52.74 |
| Tempus AI (TEM) | United States | $10.965B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.223B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.794B | 59.28 |
| Hinge Health (HNGE) | United States | $3.587B | 0.00 |
| Privia Health (PRVA) | United States | $2.402B | 164.17 |
| 10x Genomics (TXG) | United States | $1.691B | 0.00 |
| Schrodinger (SDGR) | United States | $1.650B | 0.00 |
| Phreesia (PHR) | United States | $1.610B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.565B | 0.00 |
| Azenta (AZTA) | United States | $1.555B | 72.25 |
| Enovis (ENOV) | United States | $1.551B | 8.65 |
| Omnicell (OMCL) | United States | $1.318B | 23.25 |
| Evolent Health (EVH) | United States | $1.098B | 93.50 |
| Claritev (CTEV) | United States | $0.686B | 0.00 |
| Standard BioTools (LAB) | United States | $0.558B | 0.00 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.514B | 0.00 |
| Talkspace (TALK) | United States | $0.422B | 126.00 |
| TruBridge (TBRG) | United States | $0.349B | 775.00 |
| Outset Medical (OM) | United States | $0.312B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.268B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.265B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.241B | 0.00 |
| CapsoVision (CV) | United States | $0.198B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.165B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.162B | 0.00 |
| American Well (AMWL) | United States | $0.136B | 0.00 |
| Pulmonx (LUNG) | United States | $0.133B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.116B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.115B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.106B | 0.00 |
| CareCloud (CCLD) | United States | $0.100B | 3.82 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.085B | 0.00 |
| 111 (YI) | China | $0.064B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.053B | 0.00 |
| HeartBeam (BEAT) | United States | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.027B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.022B | 0.00 |
| Precipio (PRPO) | United States | $0.021B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.015B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |